Romosozumab

• Postmenopausal Osteoporosis
• High-Risk Osteoporotic Fractures
• Severe Osteoporosis

Romosozumab, sold under the brand name Evenity, is a humanized monoclonal antibody that targets sclerostin to treat severe postmenopausal osteoporosis. It is unique among osteoporosis medications because it both stimulates new bone formation and reduces bone resorption, producing larger and faster gains in bone mineral density than any other approved therapy. That dual anabolic-antiresorptive mechanism makes it especially attractive for patients at imminent fracture risk — those with recent fractures, very low T-scores, or multiple risk factors — but it comes packaged with a boxed warning for cardiovascular events that requires careful patient selection.

Mechanism of Action

Bone is constantly remodeling, with osteoclasts removing old bone and osteoblasts laying down new matrix. The Wnt signaling pathway is one of the most important regulators of osteoblast activity: when Wnt ligands bind to LRP5 or LRP6 co-receptors on osteoblasts, downstream signaling drives proliferation, differentiation, and bone matrix deposition. Sclerostin, a glycoprotein secreted predominantly by osteocytes embedded in mature bone, binds LRP5 and LRP6 and acts as a brake on this pathway, dampening osteoblast activity. Loss-of-function mutations in the sclerostin gene cause sclerosteosis and Van Buchem disease — conditions characterized by progressive bone overgrowth — providing strong human genetic evidence that lowering sclerostin can build bone.

Romosozumab binds and neutralizes sclerostin, releasing the Wnt brake and producing a transient burst of osteoblast activity that increases bone formation markers (such as P1NP) substantially within days. Simultaneously, sclerostin inhibition modestly reduces RANKL expression and increases osteoprotegerin, lowering osteoclast activity and bone resorption markers (CTX). The anabolic window is finite — after about 12 months, formation markers return toward baseline and net bone gain plateaus, which is why treatment duration is capped at 12 monthly doses. After completing therapy, the BMD gains require maintenance with an antiresorptive agent (typically a bisphosphonate or denosumab) to prevent loss. For broader background, our osteoporosis condition page outlines the place of anabolic therapy among options.

Clinical Use

Romosozumab is FDA-approved for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as those with a history of osteoporotic fracture, multiple risk factors for fracture, or those who have failed or cannot tolerate other therapies. The pivotal FRAME trial compared romosozumab with placebo for 12 months and showed a 73 percent reduction in new vertebral fractures and significant gains in BMD. The ARCH trial compared romosozumab followed by alendronate against alendronate alone in women with prior fragility fracture and demonstrated superior fracture protection — but also revealed an imbalance in major adverse cardiovascular events, leading to the boxed warning. Within the algorithm, the Endocrine Society and the American Association of Clinical Endocrinologists recommend romosozumab as a first-line option for women with very high fracture risk, particularly those with severe osteoporosis (T-score below -2.5 with prior fracture, or T-score below -3.0). It is sequenced before bisphosphonates or denosumab in this group rather than after, because anabolic-then-antiresorptive sequencing produces greater BMD gains than the reverse order. Patient selection requires excluding those with myocardial infarction or stroke within the prior 12 months and weighing cardiovascular risk carefully in others.

How to Take It

The dose is 210 mg given monthly as two separate 105 mg subcutaneous injections at one visit, typically by a healthcare professional in the office. Injections may be given in the abdomen, thigh, or upper arm, with the two injections placed at separate sites. The full course is 12 monthly doses; therapy is not continued beyond one year because the anabolic effect plateaus. Patients should take adequate calcium (1,000 to 1,200 mg daily from diet plus supplements) and vitamin D (800 to 1,000 IU daily) throughout treatment to prevent hypocalcemia, which can occur because of the rapid bone formation drawing calcium from the circulation. If a dose is missed, it should be administered as soon as possible and the schedule reset to monthly from that date. Storage of the prefilled syringes is refrigerated at 36 to 46 degrees Fahrenheit; the syringe should reach room temperature before injection (about 30 minutes out of the refrigerator) to reduce sting. After completing romosozumab, an antiresorptive medication should be initiated promptly to maintain the BMD gains.

Monitoring and Follow-Up

Before starting, a thorough cardiovascular history is essential, including any prior MI, stroke, transient ischemic attack, or unstable angina; baseline blood pressure, lipid panel, and consideration of cardiology consultation in patients with multiple risk factors are appropriate. Baseline serum calcium must be normal — hypocalcemia must be corrected before the first dose, and 25-hydroxyvitamin D should be at least 20 to 30 ng/mL. A baseline DXA scan documents starting BMD and trabecular bone score where available. During therapy, serum calcium should be checked periodically, particularly in patients with renal impairment, where hypocalcemia risk is higher. A dental examination before starting is recommended to address periodontal disease and to plan any major dental procedures, given the small risk of osteonecrosis of the jaw. Repeat DXA scanning is typically done at the end of the 12-month course and again 12 to 24 months after transitioning to antiresorptive maintenance. Reviewing your bone density results alongside our understanding cholesterol, bone health after 50, and other cardiovascular guides supports comprehensive risk assessment.

Special Populations

Elderly patients tolerate romosozumab generally well, but cardiovascular risk rises with age, making careful selection essential. In renal impairment, dose adjustment is not formally required but hypocalcemia risk is meaningfully higher in patients with eGFR below 30 mL/min/1.73 m2 and in those on dialysis; calcium and vitamin D supplementation and frequent monitoring are critical. Hepatic impairment data are limited; no dose change is recommended. Romosozumab is not indicated in men, in premenopausal women, or in pediatric patients — efficacy and safety have not been established in these groups. Pregnancy and lactation are not relevant given the postmenopausal indication. Patients with prior atypical femur fractures or osteonecrosis of the jaw should generally avoid romosozumab. Those with active malignancy of bone or with multiple myeloma require individualized decision-making. Concurrent use with denosumab or other bone-active biologics has not been studied and is not recommended.

When to Contact Your Doctor

Seek immediate emergency care for chest pain, sudden one-sided weakness, slurred speech, facial droop, sudden vision changes, or severe shortness of breath — these may indicate myocardial infarction or stroke, both of which carry a small but real boxed-warning increase with romosozumab. Numbness, tingling, or muscle spasms (particularly in the hands, feet, or around the mouth) may signal hypocalcemia and warrant prompt evaluation. New or unusual thigh, hip, or groin pain — particularly aching or dull pain that does not resolve — should be evaluated for atypical femur fracture. Persistent jaw pain, loose teeth, exposed bone, or non-healing dental sores may indicate osteonecrosis of the jaw and require dental and oral surgical assessment. Significant injection-site reactions, hives, or any allergic symptoms after a dose should be reported. The FDA Evenity label and the NIH Bone Health Resource provide additional patient-friendly information.

Practical Tips for Daily Use

A few practical habits make the 12-month romosozumab course go more smoothly. Schedule your monthly injection appointment for the same day each month — for example, the first Tuesday — and put it in your calendar at the start of therapy so the year is mapped out. Bring a list of all medications and supplements to each visit; many patients add over-the-counter calcium or vitamin D and forget to mention it. Take your calcium supplement with meals (calcium carbonate requires stomach acid for absorption; calcium citrate does not, but both are acceptable) and split doses if you take more than 600 mg per day, since absorption is more efficient at lower doses. Vitamin D should be checked at least once during therapy to confirm adequate levels. Weight-bearing exercise — walking, light resistance training, dancing — supports bone formation and balance, both of which reduce fracture risk independently of medication. Fall-prevention measures around the home matter: removing throw rugs, installing bath grab bars, ensuring adequate lighting on stairs, and reviewing medications that contribute to dizziness all reduce the everyday fracture exposure. Schedule your transition antiresorptive medication (alendronate, zoledronic acid, or denosumab) before your final romosozumab dose so there is no gap.

Working With Your Care Team

Osteoporosis treatment is highly individualized, and choosing whether to start with an anabolic agent like romosozumab requires balancing fracture risk, cardiovascular risk, and long-term sequencing strategy. Schedule a visit with our team to review your DXA results, fracture history, and overall risk profile so we can build a coordinated plan with cardiology and dentistry as needed.